The single most important thing to understand going into this print is that HCA already told us the numbers. On July 14, 2026, HCA pre‑announced preliminary Q2 results and cut full‑year guidance in an 8‑K — a rare move that management typically reserves for material surprises. The stock fell roughly 7% on the day (from ~$390.74 on 7/13 to $363.60 on 7/14), and dragged hospital peers down with it (Tenet -5.7%, UHS -5.6%).
So tomorrow's call is not about the headline beat — it's about the narrative: how much of the guidance cut is structural vs. transitory, and what it implies for 2027, when the biggest overhang (ACA subsidy expiration) fully bites.
| Metric | Q2 2026 (prelim) | Q2 2025 | Consensus (pre-announce) |
|---|---|---|---|
| Revenue | ~$20.23B (+8.7% YoY) | $18.61B | ~$19.4B ✅ beat |
| Diluted EPS | $7.62 (+11.6% YoY) | $6.83 | ~$7.46 ✅ beat |
| Adjusted EPS | $7.59 | $6.84 | — |
| Adjusted EBITDA | $4.027B (+4.6% YoY) | $3.849B | — |
| Adj. EBITDA margin | 19.9% | 20.7% | ⚠️ -80 bps |
| Diluted shares | 222.8M | 241.9M | ~8% reduction |
The paradox of the quarter: HCA beat on revenue and EPS but cut guidance and sold off. That tension is the whole story. Two large, offsetting one-time-ish items ran through Q2:
In other words, a favorable government-payment windfall roughly masked a worsening core payer-mix problem. Investors should press management on the underlying, "clean" run-rate once these wash out.
| FY2026 Guidance | Prior (Jan 27) | Revised (Jul 14) |
|---|---|---|
| Revenue | $76.5–80.0B | $77.0–79.5B (narrowed) |
| Net income | $6.495–7.035B | $6.30–6.70B ⬇️ |
| Adjusted EBITDA | $15.55–16.45B | $15.40–16.10B ⬇️ |
| Diluted EPS | $29.10–31.50 | $28.70–30.50 ⬇️ |
| CapEx | $5.0–5.5B | Unchanged |
Key assumption revisions tell the real story:
| Assumption | Prior (Apr 24) | Revised (Jul 14) |
|---|---|---|
| Health Insurance Exchange impact | ($600)–($900)M | ($1.0)–($1.2)B ⬇️ |
| Medicaid Supplemental Payments | ($50)–($250)M | +$300–500M ⬆️ |
The exchange headwind was roughly doubled, only partially cushioned by the Florida-driven Medicaid supplemental swing to a net positive. The takeaway: the exchange deterioration is bigger and arriving faster than HCA modeled just three months ago — and the Medicaid offset is inherently lumpy and non-repeatable.
The enhanced premium tax credits (EPTCs) expire at the end of 2025, and combined with the 2025 Federal Budget Act, this is pushing exchange enrollees into the uninsured bucket. On the Q1 call, management framed exchange volume declines of 15–20%, with uninsured admissions up ~16% (over half from exchange runoff, the rest from a slowdown in Medicaid conversions — which they attributed partly to immigration-related reluctance to file applications).
Questions that matter: - Is the ~$400M Q2 payer-mix hit a new quarterly run-rate, or does it still build? - 2027 setup: this is the real fear. If ~$1.0–1.2B is the 2026 impact with subsidies only expiring at year-end 2025, what's the annualized 2027 headwind? This is what the stock is really discounting. - Any signal on Washington — will Congress extend EPTCs? Management has flagged this as a live policy debate.
Q2 same-facility trends were a study in contrasts: - Strong: Admissions +2.5%, equivalent admissions +2.7%, ER visits +3.6% - Weak: Inpatient surgeries -2.3%, outpatient surgeries -3.4%
Rising ER visits + falling surgeries = classic signature of a payer-mix downgrade (more uninsured/lower-acuity walk-ins, fewer profitable elective procedures). Demand is there; profitability of that demand is eroding. Watch acuity/case-mix commentary and whether the surgical softness is mix-driven or genuine demand loss.
EBITDA margin fell 80 bps YoY. HCA has a $400M full-year resiliency/cost program (AI, ambient documentation, nurse handoff, case management). Look for confirmation that resiliency savings are on track and offsetting mix pressure — and how AI is contributing operationally.
The Florida program approval was the swing factor to the upside this quarter. On the Q1 call, management was already "positive" on Florida. Key: how much was retroactive catch-up (non-recurring) vs. a sustainable ongoing benefit, and what remains outstanding across other states. These programs are, in management's own words, "complex, variable and difficult to predict."
HCA remains a capital-return machine — Q1 saw $1.57B in buybacks + $183M dividends, and the diluted share count fell ~8% YoY (241.9M → 222.8M). CapEx guidance held at $5.0–5.5B. With the stock beaten down, watch for aggressive repurchase commentary as a floor.
On Q1, management noted 2026 is fully contracted; they're ~1/3 through 2027 and modestly into 2028 negotiations. Given the payer/utilization-management friction (denials, Medicare Advantage), any rate-environment color for 2027–28 is valuable.
The setup is asymmetric: with numbers already known and expectations reset, the call is a narrative/sentiment event. A credible framing of the exchange headwind as manageable into 2027 — plus reassurance on volumes, resiliency, and buybacks — could support a relief move. Conversely, any hint that the payer-mix erosion is accelerating (or a soft 2027 preview) risks another leg down.
HCA's Q2 was, mechanically, a beat — but the market correctly focused on the quality of earnings (government-payment windfall masking a doubling of the ACA exchange headwind) and the forward risk (EPTC expiration fully hitting in 2027). The fundamentals of the business look intact: demand is growing (admissions +2.5%, ER +3.6%), the balance sheet is strong, and management is buying back stock aggressively into weakness. The debate is entirely about policy-driven payer mix — how deep, how durable, and how much is already in the price. Listen for management to draw a clear line between transitory (one-time mix catch-ups, Medicaid timing) and structural (uninsured growth, subsidy expiration) headwinds. That distinction will determine whether the stock has found a bottom.
Note: Preliminary figures are unaudited and subject to finalization; the July 24 release will confirm final numbers and provide full segment/cash-flow detail not included in the pre-announcement.